Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Metastatic Breast Cancer With Somatostatin Analogues—A Meta-Analysis

  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Somatostatin analogues appear to have antiproliferative effects in breast cancer by inhibiting various hormones. Several small phase 1 and 2 clinical trails have evaluated the efficacy of somatostatin analogues, but the results are varied. The purpose of this study was to use the technique of meta-analysis to determine the effect of somatostatin analogues on tumor response, toxicity, and serum hormone levels in women with metastatic breast cancer.

Methods: All published and unpublished trials were reviewed. Meta-analysis was preformed by best linear unbiased estimate regression with observations weighted inversely to their variance. Significance was considered at P < .05.

Results: Fourteen studies (N = 210) were included. Positive tumor response was reported in 87 patients (41.4%). Mean duration of response was 3.9 months. Response was best when somatostatin analogues were given as first-line therapy (69.5% versus 28.5%, P < .006) and in patients with ≤2 metastases (45.0% versus 5.6%, P = .3). Mild side effects occurred in 47 of 185 patients (25.4%). Therapy was associated with a decrease in serum insulin-like growth factor (IGF-1) and an increase in growth hormone.

Conclusions: In patients with metastatic breast cancer, treatment with somatostatin analogues was associated with a tumor response of over 40% with few side effects. Best results were achieved when somatostatin analogues were given as first-line therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Mascardo RN, Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982; 111: 1394–6.

    Article  PubMed  CAS  Google Scholar 

  2. Lamberts SWJ, Van Der Lely AJ, De Herder WW, Hoflan LJ. Octreotide. N Engl J Med 1996; 334: 246–54.

    PubMed  CAS  Google Scholar 

  3. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995; 274: 1935–8.

    PubMed  CAS  Google Scholar 

  4. Vennin P, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A. Effect of the long-acting somatostatin analogue SMS 201–995 (Sandostatin) in advanced breast cancer. Anticancer Res 1989; 9: 153–5.

    PubMed  CAS  Google Scholar 

  5. Morere JF, Cour V, Breau JL, Boaziz C, Basin C, Israel L. Stabilizing effect of BIM 23014, a long-acting somatostatin analog, in 30 cases of advanced breast cancer. A phase II study. Proc Am Soc Clin Oncol 1989; 8: A179.

    Google Scholar 

  6. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M. Endocrine effects of combined somatostatin analogue and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989; 14: 289–98.

    PubMed  CAS  Google Scholar 

  7. Stolfi R, Parisi AM, Natoli C, Iacovelli S. Advanced breast cancer: response to somatostatin. Anticancer Res 1990; 10: 203–4.

    PubMed  CAS  Google Scholar 

  8. Cannata D, Boccardo F, Canobbio L, Pensa F, Amoroso D. Somatuline plus tamoxifen in postmenopausal breast cancer patients. Ann Oncol 1992; 3: 76.

    Google Scholar 

  9. Pollack M, Poisson R, Major D, Gallant K. Octreotide with or without a prolactin-suppressive agent for patients with breast cancer refractory to antiestrogens. Proc Am Soc Clin Oncol 1992; 11: A173.

    Google Scholar 

  10. Somlo G, Vogel C, Flamm Honig S, Linnartz R, Israel R. A Phase I study of octreotide (SMS) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: A172.

    Google Scholar 

  11. Bonneterre J, Pion JM, Adenis A, Peyrat JP, Henane S, Thomas F. Bromocriptine and lanreotide in advanced breast cancer: a phase II study (meeting abstract). Eur J Cancer 1993; 29A, 584.

    Google Scholar 

  12. Anderson E, Ferguson JE, Morten H. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Eur J Cancer 1993; 29A: S121.

    Google Scholar 

  13. Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline (BIM 23014) and Tamoxifen treatment of postmenopausal breast cancer patients: Clinical activity and effect of insulin-like growth factor-1 (IGF-1) levels. Anticancer Res 1995; 15: 2687–90.

    PubMed  CAS  Google Scholar 

  14. Di Leo A, Ferrari L, Bajetta E, et al. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in treatment of advanced breast cancer. Breast Cancer Res Treat 1995; 34: 237–44.

    PubMed  CAS  Google Scholar 

  15. Ingle JN, Kardinal CG, Suman VJ, Krook JE, Hatfield AK. Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs 1996; 14: 235–7.

    PubMed  CAS  Google Scholar 

  16. Bontenbal M, Foekens JA, Lamberts SW, et al. Feasibility, endocrine and anti-tumor effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998; 77: 115–22.

    PubMed  CAS  Google Scholar 

  17. Lippman HE, Dickson EB, Gelmann EP, et al. Mechanisms of estrogenic and antiestrogenic regulation of growth of human breast carcinoma. In: Klijn JHG, ed. Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. New York: Raven Press, 1985: 381–406.

    Google Scholar 

  18. Klijn JGM, Berns PMJJ, Foekens JA. Prognostic factors and response to therapy in breast cancer. Cancer Surv 1993; 18: 165–98.

    PubMed  CAS  Google Scholar 

  19. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer. J Steroid Biochem Molec Biol 1990; 37: 977–81.

    PubMed  CAS  Google Scholar 

  20. Emerman JT, Leaky M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 1985; 17: 421–4.

    Article  PubMed  CAS  Google Scholar 

  21. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 492–7.

    PubMed  CAS  Google Scholar 

  22. RobertsCTJr, Brown AL, Graham DE, et al. Growth hormone regulates the abundance of insulin-like growth factor 1 RNA in adult rat liver. J Biol Chem 1986; 261: 10025–8.

    PubMed  CAS  Google Scholar 

  23. Hoyer D, Lubbert H, Bruns C. Molecular pharmacology of somatostatin receptors. Arch Pharm 1994; 350: 441–53.

    CAS  Google Scholar 

  24. Nelson J, Cremin M, Murphy RF. Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and Sandostatin. Br J Cancer 1989; 59: 739–42.

    PubMed  CAS  Google Scholar 

  25. Ciocca DR, Puy LA, Fasoli LC, Papa OS, Sonego R. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 1990; 15: 175–84.

    PubMed  CAS  Google Scholar 

  26. Bootsma AH, van Eijck CH, Schouten KK, et al. Somatostatin receptor-positive primary breast tumors: genetic, patient and tumor characteristics. Int J Cancer 1993; 54: 357–62.

    PubMed  CAS  Google Scholar 

  27. Reubi JC, Maurer R, von Werder K, Torhorst J, Mlijn JGM, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551–8.

    PubMed  CAS  Google Scholar 

  28. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995; 80: 2974–9.

    PubMed  CAS  Google Scholar 

  29. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3, sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70: 530–7.

    PubMed  CAS  Google Scholar 

  30. Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997; 75: 798–803.

    PubMed  CAS  Google Scholar 

  31. XuY, Song J, Berelowitz M, Bruno JF. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996; 137: 5634–40.

    PubMed  CAS  Google Scholar 

  32. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Molecular Endocrinology 1999; 13: 82–90.Jr

    PubMed  CAS  Google Scholar 

  33. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Molecular Endocrinology 1996; 10: 1688–96.

    PubMed  CAS  Google Scholar 

  34. Gaver D ed. Combining Information: Statistical Issues and Opportunities for Research. Washington, DC: National Academy Press, 1992.

    Google Scholar 

  35. Buscomb JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun 1997; 18: 698–709.

    Article  Google Scholar 

  36. VanEijck CH, Krenning EP, Bootsma A, et al., Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640–3.

    CAS  Google Scholar 

  37. McCready VR, Hickish TF. Somatostatin imaging function. Lancet 1994; 343: 617.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

    Jean T. Dolan MD, Darlene M. Miltenburg MD, Thomas S. Granchi MD, Charles C. Miller III, PhD & F. Charles Brunicardi MD

  2. Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 6550 Fannin, Suite 1661, New York, NY, 77030, Houston, Texas

    Darlene M. Miltenburg MD

Authors
  1. Jean T. Dolan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Darlene M. Miltenburg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas S. Granchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles C. Miller III, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Charles Brunicardi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Darlene M. Miltenburg MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dolan, J.T., Miltenburg, D.M., Granchi, T.S. et al. Treatment of Metastatic Breast Cancer With Somatostatin Analogues—A Meta-Analysis. Ann Surg Oncol 8, 227–233 (2001). https://doi.org/10.1007/s10434-001-0227-x

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-001-0227-x

Key Words:

Search

Navigation